Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [1967]
News [3163]
Articles [130]
Editorials [3]
Conferences [121]
elearning [17]
Novel Bcl-2 specific inhibitor updated results confirm substantial activity and...
Dr John Seymour - Peter MacCallum Cancer Centre, Melbourne, Australia
Novel Bcl-2 specific inhibitor updated results confirm substantial activity and durable responses in high-risk CLL ( Dr John Seymour - Peter MacCallum Cancer Centre, Melbourne, Australia )
19 Jun 2014
Does the use of generics of imatinib for chronic myeloid leukaemia jeopardise...
Dr Zafer Başlar - Istanbul University, Istanbul, Turkey
Does the use of generics of imatinib for chronic myeloid leukaemia jeopardise patient safety? ( Dr Zafer Başlar - Istanbul University, Istanbul, Turkey )
19 Jun 2014
Blinatumomab shown to be beneficial in relapsed/refractory B-precursor acute...
Prof Max Topp - Würzburg University Hospital, Würzburg, Germany
Blinatumomab shown to be beneficial in relapsed/refractory B-precursor acute lymphoblastic leukaemia ( Prof Max Topp - Würzburg University Hospital, Würzburg, Germany )
2 Jun 2014
ASCO 2014 roundup
Prof Gordon McVie - ecancer and European Institute of Oncology, Milan, Italy
ASCO 2014 roundup ( Prof Gordon McVie - ecancer and European Institute of Oncology, Milan, Italy )
2 Jun 2014
Mantle cell lymphoma: A review of data and expert opinion from ASCO 2014
Prof Franco Cavalli, Prof Gordon McVie
Mantle cell lymphoma: A review of data and expert opinion from ASCO 2014 ( Prof Franco Cavalli, Prof Gordon McVie )
1 Jun 2014
Ibrutinib significantly delays disease progression and extends survival in...
Dr John Byrd - The Ohio State University, Columbus, USA
Ibrutinib significantly delays disease progression and extends survival in resistant or relapsed CLL ( Dr John Byrd - The Ohio State University, Columbus, USA )
31 May 2014
Ibrutinib significantly delays disease progression and extends survival in...
Dr John Byrd - The Ohio State University, Columbus, USA
Ibrutinib significantly delays disease progression and extends survival in resistant or relapsed CLL ( Dr John Byrd - The Ohio State University, Columbus, USA )
31 May 2014
Emerging pathways in immunotherapy
Prof Christopher Höller - Medical University of Vienna, Vienna, Austria
Emerging pathways in immunotherapy ( Prof Christopher Höller - Medical University of Vienna, Vienna, Austria )
20 May 2014
Myeloma genomics and Immuno-oncology
Prof Keith Stewart; Prof Gareth Morgan; Dr Leif L. Bergsagel; Prof Antonio...
Myeloma genomics and Immuno-oncology ( Prof Keith Stewart; Prof Gareth Morgan; Dr Leif L. Bergsagel; Prof Antonio Palumbo )
15 May 2014
Novel targets and immune based therapy in myeloma
Dr Kenneth Anderson; Prof Antonio Palumbo; Prof Gareth Morgan; Prof Jesús San...
Novel targets and immune based therapy in myeloma ( Dr Kenneth Anderson; Prof Antonio Palumbo; Prof Gareth Morgan; Prof Jesús San Miguel )
15 May 2014
Upcoming trends in myeloma therapy
Dr Kenneth Anderson; Prof Gareth Morgan; Prof Paul Richardson
Upcoming trends in myeloma therapy ( Dr Kenneth Anderson; Prof Gareth Morgan; Prof Paul Richardson )
15 May 2014
Recent advances in mantle cell lymphoma: Expert panel discussion
Prof Simon Rule; Prof Umberto Vitolo; Prof Pier Luigi Zinzani; Prof Emanuele...
Recent advances in mantle cell lymphoma: Expert panel discussion ( Prof Simon Rule; Prof Umberto Vitolo; Prof Pier Luigi Zinzani; Prof Emanuele Zucci )
13 May 2014

More from ecancer

Register with ecancer to receive our newsletter

Register here

Explore patient resources at ecancerpatient

Visit site

Find out more about ecancer and the work we do

About ecancer

Support ecancer's work by making a donation